Cargando…

Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance

BACKGROUND: RNA viruses rapidly accumulate genetic variation, which can give rise to synthetic lethal (SL) and deleterious (SD) mutations. Synthetic lethal mutations (non-lethal when alone but lethal when combined in one genome) have been studied to develop cancer therapies. This principle can also...

Descripción completa

Detalles Bibliográficos
Autores principales: Petitjean, Michel, Badel, Anne, Veitia, Reiner A, Vanet, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399722/
https://www.ncbi.nlm.nih.gov/pubmed/25888435
http://dx.doi.org/10.1186/s13062-015-0044-y
_version_ 1782366962575212544
author Petitjean, Michel
Badel, Anne
Veitia, Reiner A
Vanet, Anne
author_facet Petitjean, Michel
Badel, Anne
Veitia, Reiner A
Vanet, Anne
author_sort Petitjean, Michel
collection PubMed
description BACKGROUND: RNA viruses rapidly accumulate genetic variation, which can give rise to synthetic lethal (SL) and deleterious (SD) mutations. Synthetic lethal mutations (non-lethal when alone but lethal when combined in one genome) have been studied to develop cancer therapies. This principle can also be used against fast-evolving RNA-viruses. Indeed, targeting protein sites involved in SD + SL interactions with a drug would render any mutation of such sites, lethal. RESULTS: Here, we set up a strategy to detect intragenic pairs of SL and SD at the surface of the protein to predict less escapable drug target sites. For this, we detected SD + SL, studying HIV protease (PR) and reverse transcriptase (RT) sequence alignments from two groups of VIH(+) individuals: treated with drugs (T) or not (NT). Using a series of statistical approaches, we were able to propose bona fide SD + SL couples. When focusing on spatially close co-variant SD + SL couples at the surface of the protein, we found 5 SD + SL groups (2 in the protease and 3 in the reverse transcriptase), which could be good candidates to form pockets to accommodate potential drugs. CONCLUSIONS: Thus, designing drugs targeting these specific SD + SL groups would not allow the virus to mutate any residue involved in such groups without losing an essential function. Moreover, we also show that the selection pressure induced by the treatment leads to the appearance of new mutations, which change the mutational landscape of the protein. This drives the existence of differential SD + SL couples between the drug-treated and non-treated groups. Thus, new anti-viral drugs should be designed differently to target such groups. REVIEWERS: This article was reviewed by Neil Greenspan Csaba Pal and István Simon. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13062-015-0044-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4399722
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43997222015-04-17 Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance Petitjean, Michel Badel, Anne Veitia, Reiner A Vanet, Anne Biol Direct Research BACKGROUND: RNA viruses rapidly accumulate genetic variation, which can give rise to synthetic lethal (SL) and deleterious (SD) mutations. Synthetic lethal mutations (non-lethal when alone but lethal when combined in one genome) have been studied to develop cancer therapies. This principle can also be used against fast-evolving RNA-viruses. Indeed, targeting protein sites involved in SD + SL interactions with a drug would render any mutation of such sites, lethal. RESULTS: Here, we set up a strategy to detect intragenic pairs of SL and SD at the surface of the protein to predict less escapable drug target sites. For this, we detected SD + SL, studying HIV protease (PR) and reverse transcriptase (RT) sequence alignments from two groups of VIH(+) individuals: treated with drugs (T) or not (NT). Using a series of statistical approaches, we were able to propose bona fide SD + SL couples. When focusing on spatially close co-variant SD + SL couples at the surface of the protein, we found 5 SD + SL groups (2 in the protease and 3 in the reverse transcriptase), which could be good candidates to form pockets to accommodate potential drugs. CONCLUSIONS: Thus, designing drugs targeting these specific SD + SL groups would not allow the virus to mutate any residue involved in such groups without losing an essential function. Moreover, we also show that the selection pressure induced by the treatment leads to the appearance of new mutations, which change the mutational landscape of the protein. This drives the existence of differential SD + SL couples between the drug-treated and non-treated groups. Thus, new anti-viral drugs should be designed differently to target such groups. REVIEWERS: This article was reviewed by Neil Greenspan Csaba Pal and István Simon. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13062-015-0044-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-17 /pmc/articles/PMC4399722/ /pubmed/25888435 http://dx.doi.org/10.1186/s13062-015-0044-y Text en © Petitjean et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Petitjean, Michel
Badel, Anne
Veitia, Reiner A
Vanet, Anne
Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance
title Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance
title_full Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance
title_fullStr Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance
title_full_unstemmed Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance
title_short Synthetic lethals in HIV: ways to avoid drug resistance: Running title: Preventing HIV resistance
title_sort synthetic lethals in hiv: ways to avoid drug resistance: running title: preventing hiv resistance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399722/
https://www.ncbi.nlm.nih.gov/pubmed/25888435
http://dx.doi.org/10.1186/s13062-015-0044-y
work_keys_str_mv AT petitjeanmichel syntheticlethalsinhivwaystoavoiddrugresistancerunningtitlepreventinghivresistance
AT badelanne syntheticlethalsinhivwaystoavoiddrugresistancerunningtitlepreventinghivresistance
AT veitiareinera syntheticlethalsinhivwaystoavoiddrugresistancerunningtitlepreventinghivresistance
AT vanetanne syntheticlethalsinhivwaystoavoiddrugresistancerunningtitlepreventinghivresistance